Literature DB >> 19050243

TLR9-activating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B cells.

Isabelle Bekeredjian-Ding1, Anne Doster, Martin Schiller, Petra Heyder, Hanns-Martin Lorenz, Burkhart Schraven, Ursula Bommhardt, Klaus Heeg.   

Abstract

In the past, ZAP70 was considered a T cell-specific kinase, and its aberrant expression in B-CLL cells was interpreted as a sign of malignant transformation and dedifferentiation. It was only recently that ZAP70 was detected in normal human B cells. In this study, we show that TLR9-activated B cells resemble B-cell chronic lymphocytic leukemia cells with regard to CD5, CD23, CD25, and heat shock protein 90 expression. Furthermore, stimulatory CpG and GpC DNA oligonucleotides target CD27(+)IgM(+) and CD27(-)IgM(+) B cells (but not IgM(-) B cells) and enhance ZAP70 expression predominantly in the IgM(+)CD27(+) B cell subset. ZAP70 is induced via activation of TLR-7 or -9 in a MyD88-dependent manner, depends on protein kinase B (PKB)/mammalian target of rapamycin signaling and is rapamycin sensitive. Furthermore, ZAP70 expression levels correlate with induction of cyclin A2, prolonged B cell proliferation, and sustained induction of PKB. These events are not observed upon CD40 ligation. However, this deficit can be overcome by the expression of constitutively active PKB, given that CD40 ligation of PKB-transgenic B cells induces B cell proliferation and ZAP70 expression. These results highlight a major difference between CD40- and TLR-7/9-mediated B cell activation and suggest that ZAP70 expression levels in B cells give an estimate of the proliferative potential and the associated PKB availability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050243     DOI: 10.4049/jimmunol.181.12.8267

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

2.  B Cells Produce Type 1 IFNs in Response to the TLR9 Agonist CpG-A Conjugated to Cationic Lipids.

Authors:  Munir Akkaya; Billur Akkaya; Pietro Miozzo; Mukul Rawat; Mirna Pena; Patrick W Sheehan; Ann S Kim; Olena Kamenyeva; Juraj Kabat; Silvia Bolland; Akanksha Chaturvedi; Susan K Pierce
Journal:  J Immunol       Date:  2017-06-26       Impact factor: 5.422

3.  Toll-like receptor 7 and 9 defects in common variable immunodeficiency.

Authors:  Joyce E Yu; Adina K Knight; Lin Radigan; Thomas U Marron; Li Zhang; Silvia Sanchez-Ramón; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2009-07-09       Impact factor: 10.793

Review 4.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 5.  New insights into the regulation of human B-cell differentiation.

Authors:  Heike Schmidlin; Sean A Diehl; Bianca Blom
Journal:  Trends Immunol       Date:  2009-05-15       Impact factor: 16.687

6.  Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils.

Authors:  Kang Chen; Weifeng Xu; Melanie Wilson; Bing He; Norman W Miller; Eva Bengtén; Eva-Stina Edholm; Paul A Santini; Poonam Rath; April Chiu; Marco Cattalini; Jiri Litzman; James B Bussel; Bihui Huang; Antonella Meini; Kristian Riesbeck; Charlotte Cunningham-Rundles; Alessandro Plebani; Andrea Cerutti
Journal:  Nat Immunol       Date:  2009-06-28       Impact factor: 25.606

7.  A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness.

Authors:  Andriy V Kubarenko; Satish Ranjan; Anna Rautanen; Tara C Mills; Sunny Wong; Fredrik Vannberg; Michael Neumaier; Isabelle Bekeredjian-Ding; Adrian V S Hill; Parviz Ahmad-Nejad; Alexander N R Weber
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

8.  Phosphorothioate-modified CpG oligodeoxynucleotides mimic autoantigens and reveal a potential role for Toll-like receptor 9 in receptor revision.

Authors:  Anne Doster; Saskia Ziegler; Sandra Foermer; Ralf Joachim Rieker; Klaus Heeg; Isabelle Bekeredjian-Ding
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

9.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

10.  Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.

Authors:  Olga Ticha; Lukas Moos; Harald Wajant; Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2018-01-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.